Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 16;17(1):27.
doi: 10.1186/s11671-022-03668-6.

Nanoscale Drug Delivery Systems in Glioblastoma

Affiliations
Review

Nanoscale Drug Delivery Systems in Glioblastoma

Zihao Liu et al. Nanoscale Res Lett. .

Abstract

Glioblastoma is the most aggressive cerebral tumor in adults. However, the current pharmaceuticals in GBM treatment are mainly restricted to few chemotherapeutic drugs and have limited efficacy. Therefore, various nanoscale biomaterials that possess distinct structure and unique property were constructed as vehicles to precisely deliver molecules with potential therapeutic effect. In this review, nanoparticle drug delivery systems including CNTs, GBNs, C-dots, MOFs, Liposomes, MSNs, GNPs, PMs, Dendrimers and Nanogel were exemplified. The advantages and disadvantages of these nanoparticles in GBM treatment were illustrated.

Keywords: Biomaterials; Drug delivery systems; Glioblastoma; Nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Conceptual diagrams of single-walled carbon nanotubes (SWCNT) (a) and multi-walled carbon nanotubes (MWCNT) (b). Referred from [23], OA
Fig. 2
Fig. 2
a Two main routes to prepare GBNs: “Top-down” splitting approach and “Bottom-up” synthesis approach. b Classifications of graphenes based on lateral size. The GQDs represent graphene quantum dots. Referred from [34] with permission
Fig. 3
Fig. 3
a Crystal structures of different MOFs. b High resolution TEM image of Uio-66. Referred from [64, 65] with permission
Fig. 4
Fig. 4
The structure, vesicle size (a) and lamellarity classification (b) of liposome drug delivery systems. c, d The cryo-electron tomography liposomes Doxil structure with the liposome density shown in purple and doxorubicin density shown in pink. Referred from [74, 75] with permission
Fig. 5
Fig. 5
The TEM images of gold nanoparticles with cage-like (a), cylindrical (b), triangular (c) and hexagonal (d) morphologies. Referred from [–114] with permission
Fig. 6
Fig. 6
a Schematic illustration of the core–shell structure of a polymer micelle. b Cryogenic transmission electron microscopy (cryo-TEM), tomography (cryo-ET) and computational 3D reconstruction of multicompartment micelles. Referred from [135, 136] respectively with permission
Fig. 7
Fig. 7
Schematic representation of pharmaceutical applications of dendrimers. Referred from [164] with permission
Fig. 8
Fig. 8
Schematic representation of the network construction of hydrogels, micelles, nanogels and microgels. Referred from [175] with permission
Fig. 9
Fig. 9
a Schematic representation of the conceptual passive targeting (EPR effect) of nanomedicine. b Active targeting of nanomedicine grafted with peptide or antibody able to bind specific receptors overexpressed by (1) cancer cells or (2) endothelial cells. Referred from [199] with permission

References

    1. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073–1113. - PMC - PubMed
    1. Li J, Zhao J, Tan T, Liu M, Zeng Z, Zeng Y, et al. Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review. Int J Nanomedicine. 2020;15:2563–2582. - PMC - PubMed
    1. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3–14. - PMC - PubMed
    1. Liu HM, Liu XF, Yao JL, Wang CL, Yu Y, Wang R. Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1. J Pharmacol Exp Ther. 2006;319(1):308–316. - PubMed
    1. Dollinger S, Lober S, Klingenstein R, Korth C, Gmeiner P. A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations. J Med Chem. 2006;49(22):6591–6595. - PubMed

LinkOut - more resources